Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H7XJ
|
||||
Former ID |
DIB002791
|
||||
Drug Name |
ASP-9521
|
||||
Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Phase 1/2 | [523469] | ||
Company |
Astellas Pharma Inc
|
||||
Structure |
Download2D MOL |
||||
Target and Pathway | |||||
Target(s) | Aldo-keto reductase family 1 member C3 | Target Info | Modulator | [532753], [532866] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
Reactome | Retinoid metabolism and transport | ||||
References | |||||
Ref 532753 | Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004. | ||||
Ref 532866 | In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5; AKR1C3). Invest New Drugs. 2014 Oct;32(5):860-70. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.